Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Interventions: Arm A , Arm B, Arm C, & Arm D; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Kidney Stone, Benign Prostatic Hyperplasia
Interventions: WellPrept, Standard Care; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Postoperative, Opioid Misuse, Opioid Use, Pain
Interventions: OxyCODONE 5 mg Oral Tablet, Acetaminophen 500 mg Tab, Ibuprofen 600 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Lomecel-B medicinal signaling cells; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: HIV Infections With Multi Drug Resistant Virus
Interventions: Fostemsavir; Drug
Lead sponsor: PENTA Foundation; Network
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer
Interventions: Abiraterone - Usual, Abiraterone - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 22 Years to 75 Years · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Endometrial Cancer
Interventions: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 57
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more

Conditions: Papillomavirus Infections
Interventions: 9vHPV vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 26 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Daly City, California • Oakland, California • Roseville, California + 10 more

Conditions: Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Bipolar
Interventions: BrainSonix Pulsar 1002; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions: Glucagon for Injection (Fresenius Kabi USA); Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
Interventions: Prebiotic, Probiotic; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Ceralasertib, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Irvine, California • Los Angeles, California • Orange, California + 16 more

Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Interventions: Fludarabine, Cyclophosphamide, CD19-CD34 CAR transduced T cells; Drug · Biological
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer
Interventions: Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad pegol (ACP); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Not listed
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Active Comparator, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 50
States / cities: Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lymph Node Involvement, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy; Radiation
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Adenocarcinoma
Interventions: Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11, Positron Emission Tomography; Procedure · Drug · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: COVID-19
Interventions: Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Fair Oaks, California • Doral, Florida • Atlanta, Georgia + 16 more

Conditions: Early Stage Breast Cancer
Interventions: IORT; Device
Lead sponsor: MedStar Franklin Square Medical Center; Other
Eligibility: 40 Years to 100 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

Reduced Opioid Prescription After Laparoscopic Hysterectomy

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Low-Intensity Focused Ultrasound of the Amygdala for Bipolar Disorder

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients